BenzingaSeptember 28, 2026 at 10:00 AM NY29 Days Ago
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
